Search research articles
Contact Us
Filters
Showing results (151-160 of 165) with videos related to
Page
of 17
Sort By:
Endocrine Pathology
|
October 10, 2024
High-Grade Progression, Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms (PitNENs): The UCSF Experience
Merryl Terry, Minh P Nguyen, Vivian Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2018
Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy
Eshini Panditharatna, Lindsay B Kilburn, Mariam S Aboian, et al.
Acta Neuropathologica
|
November 26, 2021
EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma
Calixto-Hope G Lucas, Rohit Gupta, Jasper Wu, et al.
Journal of Neuro-Oncology
|
March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study
Whitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
Brain Pathology (Zurich, Switzerland)
|
May 20, 2019
High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication-a comprehensive clinical, radiographic, pathologic, and genomic analysis
Sean P Ferris, Jose Velazquez Vega, Mariam Aboian, et al.
Neuro-Oncology
|
April 29, 2017
Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy
Cassie N Kline, Nancy M Joseph, James P Grenert, et al.
Neuro-Oncology
|
April 8, 2022
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes
Yalan Zhang, Calixto-Hope G Lucas, Jacob S Young, et al.
The Lancet. Oncology
|
June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Science (New York, N.Y.)
|
December 17, 2013
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Brett E Johnson, Tali Mazor, Chibo Hong, et al.
Acta Neuropathologica
|
September 14, 2019
Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas
Emily A Sloan, Tabitha Cooney, Nancy Ann Oberheim Bush, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 165) with videos related to
Sort By:
Page
of 17
Endocrine Pathology
|
October 10, 2024
High-Grade Progression, Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms (PitNENs): The UCSF Experience
Merryl Terry, Minh P Nguyen, Vivian Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2018
Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy
Eshini Panditharatna, Lindsay B Kilburn, Mariam S Aboian, et al.
Acta Neuropathologica
|
November 26, 2021
EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma
Calixto-Hope G Lucas, Rohit Gupta, Jasper Wu, et al.
Journal of Neuro-Oncology
|
March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study
Whitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
Brain Pathology (Zurich, Switzerland)
|
May 20, 2019
High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication-a comprehensive clinical, radiographic, pathologic, and genomic analysis
Sean P Ferris, Jose Velazquez Vega, Mariam Aboian, et al.
Neuro-Oncology
|
April 29, 2017
Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy
Cassie N Kline, Nancy M Joseph, James P Grenert, et al.
Neuro-Oncology
|
April 8, 2022
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes
Yalan Zhang, Calixto-Hope G Lucas, Jacob S Young, et al.
The Lancet. Oncology
|
June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Science (New York, N.Y.)
|
December 17, 2013
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Brett E Johnson, Tali Mazor, Chibo Hong, et al.
Acta Neuropathologica
|
September 14, 2019
Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas
Emily A Sloan, Tabitha Cooney, Nancy Ann Oberheim Bush, et al.
Page
of 17